During the corresponding time, X4 Pharmaceuticals Inc saw a revenue deteriorated by -90.6 % year on year, sequentially revenue grew by 5.45 %. While revenue at the X4 Pharmaceuticals Inc's corporate clients
X4 Pharmaceuticals Inc's Comment on Sales, Marketing and Customers
The company markets and sells its drug product for all indications, including WHIM syndrome and CN, in the European Economic Area, Switzerland, the United Kingdom, Australia, and New Zealand. It has an agreement with Taiba Middle East Fz LLC to distribute and commercialize XOLREMDI for WHIM syndrome in select Middle East and North African countries. The company holds a license agreement with Abbisko Therapeutics Co. Ltd., granting Abbisko exclusive rights for regulatory activities, manufacturing, and distribution of mavorixafor in mainland China, Taiwan, Hong Kong, and Macau. Additionally, the company has a license agreement with Genzyme Corporation, a subsidiary of Sanofi, for exclusive rights related to the CXCR4 receptor to develop and commercialize products including mavorixafor. Under this agreement, the company is responsible for patent activities and obligated to develop and commercialize licensed products in the United States and at least one other major market country. The Genzyme agreement includes regulatory and sales milestones, with payments contingent on achievements such as European Medicines Agency drug application acceptance and cumulative net sales targets.
X4 Pharmaceuticals Reports Promising Phase 2 Results for Mavorixafor in Chronic Neutropenia X4 Pharmaceuticals recently celebrated a significant milestone in their clinical research journey with the announcement of positive results from their completed six-month Phase 2 trial investigating mavorixafor for the treatment of chronic neutropenia (CN). This key finding has the potential to reshape the landscape for patients suffering from CN, a condition characterized by persistently low levels of neutrophils a type of white blood cell essential for fighting off infections. Understanding Chronic NeutropeniaChronic neutropenia can lead to a myriad of health problems, primarily because low neutrophil counts leave i...
In the world of pharmaceutical sciences, breakthrough clinical data from ongoing trials is always eagerly awaited. X4 Pharmaceuticals is set to host a virtual investor event on June 27, 2024, to review the impressive new findings from their Phase 2 trial in Chronic Neutropenia (CN). This event will not only unveil interim hematological results from at least 15 trial participants but also feature renowned experts in the treatment of CN. Let us delve into the facts and assess their potential impact on the company.1. New Mavorixafor Clinical Data:X4 Pharmaceuticals virtual investor event aims to present the latest insights from the ongoing Phase 2 trial of Mavorixafor in Chronic Neutropenia. Mavorixafor is an ...
X4 Pharmaceuticals Inc’s Comment on Sales, Marketing and Customers
The company markets and sells its drug product for all indications, including WHIM syndrome and CN, in the European Economic Area, Switzerland, the United Kingdom, Australia, and New Zealand. It has an agreement with Taiba Middle East Fz LLC to distribute and commercialize XOLREMDI for WHIM syndrome in select Middle East and North African countries. The company holds a license agreement with Abbisko Therapeutics Co. Ltd., granting Abbisko exclusive rights for regulatory activities, manufacturing, and distribution of mavorixafor in mainland China, Taiwan, Hong Kong, and Macau. Additionally, the company has a license agreement with Genzyme Corporation, a subsidiary of Sanofi, for exclusive rights related to the CXCR4 receptor to develop and commercialize products including mavorixafor. Under this agreement, the company is responsible for patent activities and obligated to develop and commercialize licensed products in the United States and at least one other major market country. The Genzyme agreement includes regulatory and sales milestones, with payments contingent on achievements such as European Medicines Agency drug application acceptance and cumulative net sales targets.
Sources:
X4 Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: X4 Pharmaceuticals Inc’s corporate clients.
For your research, we’ve provided 9 tables on X4 Pharmaceuticals Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
1102.51 %